Serum β₂-Microglobulin and Serum Thymidine Kinase are Independent Predictors of Progression-Free Survival in Chronic Lymphocytic Leukemia and Immunocytoma

References

• Lennert K., Feller A. C. Histopathologie der Non-Hodgkin-Lymphome (nach der aktualisierten Kiel-Klassifikation). Springer-Verlag, Berlin 1990
   Google Scholar
• Stansfeld A. G., Diebold J., Kapanoi Y., KelÉNy G., Lennert K., Mioduszewska O., Noel H., Rilke F., Sundstrom C., Van Unnik J. A. M., Wright D. H. Updated Kiel classification for lymphomas. Lancet 1988; i: 292–293
   Google Scholar
• Lennert K., Mohri N., Stein H., Kaiserling E. The histopathology of malignant lymphoma. Br. J. Haematol. 1975; 31: 193–203
   PubMed Web of Science ®Google Scholar
• Longo D. L., De Vita V. T., Jr., Jaffe E. S., Mauch P., Urba W. J. Lymphocytic lymphomas. Cancer: Principles & Practice of Oncology, V. T. De Vita, Jr., S. Hellman, S. A. Rosenberg. J. B. Lippincott Co., Philadelphia 1993; 1859–1927
   Google Scholar
• Binet J. L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M. T., Monconduit M., Belabbes S., Gremy F. A new prognostic classification of chronic lymphatic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–204
   PubMed Web of Science ®Google Scholar
• Rai K., Sawitsky A., Cronkite E., Chanana A. B., Lee R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging and response criteria. Ann. Intern. Med. 1989; 110: 236–238
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Mick R., McLntyre O. K. Pentostatin in chronic lymphocytic leukemia: A phase II trial of cancer and leukemia group B. J. Clin. Oncol. 1989; 7: 433–438
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., Redman J., Roller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Cheson B. The purine analogs—a therapeutic beauty contest. J. Clin. Oncol. 1992; 10: 352–355
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lympocytic leukemia. Blood 1988; 72: 1069–73
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock H. W. L., Schlag R., Flieger D., Thiel E. Favorable response of early response B-CLL patients to treatment with IFN-alpha. Blood 1989; 73: 1426–1430
   PubMed Web of Science ®Google Scholar
• Pangalis G. A., Griva E. Recombinant alpha-2b interferon in untreated stages A and B chronic lymphocytic leukemia: a preliminary report. Cancer 1988; 61: 869–872
   PubMed Web of Science ®Google Scholar
• Roth M. S., Foon K. A. Alpha interferon in the treatment of hematologic malignancies. Am. J. Med. 1986; 67: 216–220
   Google Scholar
• Rozman C., Montserrat E., Vinolas N., Urbano-Ispizua A., Ribera J. M., Gallart T., Compernolle C. Recombinant alpha-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood 1988; 71: 1295–1298
   PubMed Web of Science ®Google Scholar
• Foon K. A., Sherwin S. A., Abrams P. G., Al E. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N. Engl. J. Med. 1984; 311: 1148–1152
   PubMed Web of Science ®Google Scholar
• Bandini G., Michallet M., Rosti M., Tura S. Bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1991; 7: 101–103
   Google Scholar
• Bandini G., Michallet M. High-dose therapy and allogeneic bone marrow transplantation in chronic lymphocytic leukemia. High-dose cancer therapy. Pharmacology, hematopoietins, stem cells, J. O. Armitage, K. H. Antman. Williams & Wilkins, Baltimore 1992; 626–637
   Google Scholar
• Rabinowe S. N., Soiffer R. J., Gribben J. G., Daley H., Freedman A. S., Daley J., Pesek K., Neuberg D., Pinkus G., Leavitt P. R., Spector N. A., Grossbard M. L., Anderson K., Robertson M. J., Mauch P., Chayt-Marcus K., Ritz J., Nadler L. M. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–1376
   PubMed Web of Science ®Google Scholar
• Khouri I. F., Keating M. J., Vriesendorp H. M., Reading C., Przepiorka D., Huh Y. O., Andersson B. S., Van Besien K. W., Mehra R. C., Giralt S. A., Ippoliti C., Marshall M., Thomas M. W., O'Brien S., Robertson L. E., Deisseroth A. B., Champlin R. E. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J. Clin. Oncol. 1994; 12: 748–758
   PubMed Web of Science ®Google Scholar
• Dighiero G., Travade P., Chevret S., Fenaux P., Chastang C., Binet J. L., The French Cooperative Group on CLL. B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991; 78: 1901–1914
   PubMed Web of Science ®Google Scholar
• Foon K. A., Rai K. R., Gale R. P. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intern. Med. 1990; 113: 525–539
   PubMed Web of Science ®Google Scholar
• Rozman C., Montserrat E. Chronic lymphocytic leukaemia: when and how to treat. Blut 1989; 59: 467–474
   PubMedGoogle Scholar
• Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78: 895–9
   PubMed Web of Science ®Google Scholar
• Rai K. R., Rabinowe S. N. Chronic lymphocytic leukemia. Cancer Medicine, J. F. Holland, E. Frei, III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, R. R. Weichselbaum. Lea & Febiger, Philadelphia 1993; 1971–1988
   Google Scholar
• Engelhard M., Brittinger G., Heinz R., Theml H., Bartels H., Binder T., FÜLle H. H., Gerhartz H., Gunzer U., Ludwig F., Ludwig W. D., Nowicki L., Oertel J., Pees H. W., Pralle H., RÜHl U., Von Schilling C., Spann W., Stacher A., Szeimies U., Wetzel H. J., Zwingers T., Feller A. C., Stein H., Lennert K. Chronic lymphocytic leukemia (B-CLL) and immunocytoma (LPIC): clinical and prognostic relevance of this distinction. Leuk. Lymphoma 1993; 161–173, Suppl.
   Web of Science ®Google Scholar
• Facon T., Brouillard M., Duhamel A., Morel P., Simon M., Jouet J. P., Bauters F., Fenaux P. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J. Clin. Oncol. 1993; 11: 1553–1558
   PubMed Web of Science ®Google Scholar
• Gobbi P. G., Bettini R., Montencucco C., Cavanna L., Morandi S., Pieresca C., Merlini G., Bertolini D., Grignani G., Pozzetti U., Caporali R., Ascari E. Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83: 2939–2945
   PubMed Web of Science ®Google Scholar
• Ellims P. H., Eng Gan T., Medley G., Van Der Weyden M. B. Prognostic relevance of thymidine kinase in adult non-Hodgkin's lymphoma. Blood 1981; 58: 926–930
   PubMed Web of Science ®Google Scholar
• Gronowitz J. S., Hagberg H., KÄLlander C. F. R., Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br. J. Cancer 1983; 47: 487–495
   PubMed Web of Science ®Google Scholar
• Hagberg H., Glimelius B., Gronowitz J. S., Killander A., Kallander C. F. R., SchrÖDer T. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis. Scand. J. Haematol. 1984; 33: 59–67
   PubMedGoogle Scholar
• Hallek M., Emmerich B., Strohmeyer S., Busch R., Reichle A., Senekowitsch R. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors. Klin. Wochenschr. 1988; 66: 718–723
   PubMedGoogle Scholar
• Hallek M., Schick H. D., Busch R., Strohmeyer S., Wanders L., Emmerich B. Serum thymidine kinase in low and intermediate grade non-Hodgkin's lymphoma. Folia Oncol. 1990; 13: 87–91
   Google Scholar
• Hallek M., Wanders L., Schick H. D., Busch R., Senekowitsch R., Emmerich B., Rastetter J. Factors predicting the risk of progression in low and intermediate grade non-Hodgkin's lymphoma (NHL): a multivariate analysis (abstr.). Proc. Am. Soc. Clin. Oncol. 1990; 9: 272
   Google Scholar
• KÄLlander C. F. R., Simonsson B., Hagberg H., Gronowitz J. S. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 1984; 54: 2450–2455
   PubMed Web of Science ®Google Scholar
• Martinsson U., Glimelius B., Hagberg H., Sundstrom C. Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas. Eur. J. Haematol. 1988; 40: 289–98
   PubMed Web of Science ®Google Scholar
• Martinsson U., Glimelius B., Hagberg H., Sundstrom C. Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival. Eur. J. Haematol. 1989; 43: 332–8
   PubMed Web of Science ®Google Scholar
• Simonsson B., Wibell L., Nilsson K. β2-microglobulin in chronic lymphocytic leukaemia. Scand. J. Haematol. 1980; 24: 174–180
   PubMedGoogle Scholar
• Simonsson B., Brenning G., Kallander C., Ahre A. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma. Eur. J. Clin. Invest. 1987; 17: 336–9
   PubMed Web of Science ®Google Scholar
• SpÄTi B., Child J. A., Kerruish S. M., Cooper E. H. Behaviour of serum β2-microglobulin and acute phase reactant protein in chronic lymphocytic leukemia. Acta haemat. 1980; 64: 79–86
   PubMed Web of Science ®Google Scholar
• Knospe W. H., Loeb V., Jr., Huguley C. M., Jr. Biweekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 1974; 33: 555–562
   PubMed Web of Science ®Google Scholar
• Bagley C. M., De Vita V. T., Jr., Berard C. W., Canellos G. P. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann. Intern. Med. 1972; 76: 227–234
   PubMed Web of Science ®Google Scholar
• Karnofsky D. A., Abelman W. H., Craver L. F., Burchenal J. H. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634–639
   Web of Science ®Google Scholar
• Gronowitz J. S., Hagberg H., Kallander C. F. R., Simonsson B. Optimized assay for thymidine kinase and its application for the detection of antibodies against herpes simplex virus type 1-and 2-induced thymidine kinase. Infect. Immun. 1980; 29: 425–434
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 157–181
   Web of Science ®Google Scholar
• Cox D. Regression model and life-tables (with discussion). J. R. Stat. Soc. 1972; 34: 187–220
   Google Scholar
• Rodriguez J., Cabanillas F., McLaughlin P., Swan F., Rodriguez M., Hagemeister F., Romaguera J. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the ‘tumor score’. Ann. Oncol. 1992; 3: 711–717
   PubMed Web of Science ®Google Scholar
• Langenmayer I., Schlag R., Hallek M., Dietzfelbinger H., Nehrl C., Knauf W., Maubach P., Ziegler-Heitbrock H. W. L., Thiel E., Emmerich B. Interferon alpha 2b in the treatment of early stage CLL with risk for progression. First report of a randomized multicenter AIO study (abstr.). Ann. Hematol. 1991; 63: A98
   Google Scholar
• Knauf W., Langenmayer I., Nerl C., Dietzfelbinger H., Maubach P., Ziegler-Heitbrock H. W. L., Emmerich B., Thiel E. Interferon-alpha2b for early phase chronic lymphocytic leukemia with high risk for progression—first results of a randomized multicenter AIO-study. Onkologie 1992; 15: 55–7
   Web of Science ®Google Scholar
• Rozman C., Montserrat E., Rodriguez-Fernandez J. M., Ayats R., Vallespi T., Parodi R., Rios A., Prados D., Morey M., Gomis F., Alcata A., Gutierrez M., Maldonado J., Gonzalez C., Giralt M., Hernandez-Nieto L., Cabrena A., Fernandez-Ranada J. M. Bone marrow histology pattern. The best single prognostic parameter in chronic lymphocytic leukemia. A multivariate analysis of 329 cases. Blood 1984; 64: 642
   PubMed Web of Science ®Google Scholar
• Geisler C. H., Larson J. K., Hansen N. E., Hansen M. M., Christensen B. E., Lund B., Nielsen H., Plesner T., Thorling K., Andersen E., Andersen P. K. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991; 78: 1795–1802
   PubMed Web of Science ®Google Scholar
• Montserrat E., Vinolas N., Reverter J. C., Rozman C. Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early clinical stages. Nouv. Rev. Fr. Hematol. 1988; 30: 359–361
   PubMedGoogle Scholar
• Abbas A. K., Lichtman A. H., Pober J. S. Molecular and cellular immunology. W. B. Saunders Company, Philadelphia 1991
   Google Scholar
• Reichard P., Estborn B. Utilization of deoxyribosides in the synthesis of polynucleotides. J. Biol. Chem. 1951; 188: 839–846
   PubMed Web of Science ®Google Scholar
• Kit S. Viral-associated and induced enzymes. Pharmacol. Therapeut. 1979; 4: 501–585
   Web of Science ®Google Scholar
• Bello L. J. Regulation of thymidine kinase synthesis in human cells. Exp. Cell. Res. 1974; 89: 263–274
   PubMed Web of Science ®Google Scholar
• Gronowitz J. S., KÄLlander C. F. R., Diderholm H., Hagberg H., Petterson U. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int. J. Cancer 1984; 33: 5–12
   PubMed Web of Science ®Google Scholar
• Pardee A. B. Gl events and regulation of cell proliferation. Science 1989; 246: 603–608
   PubMed Web of Science ®Google Scholar
• KÄLlander C. F. R., Simonsson B., Gronowitz J. S., Nilsson K. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur. J. Haematol. 1987; 38: 331–337
   PubMed Web of Science ®Google Scholar
• Lehtinen M., Wigren T., Lehtinen T., Kallioniemi O. P., Aine R., Aaran R. K., Ojala A. Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer. Tumour Biol. 1988; 9: 287–92
   PubMed Web of Science ®Google Scholar
• McKenna P. G., O'Neill K. L., Abram W. P., Hannigan B. M. Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients. Br. J. Cancer 1988; 57: 619–22
   PubMed Web of Science ®Google Scholar
• Hallek M., Wanders L., Strohmeyer S., Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann. Hematol. 1992; 65: 1–5
   PubMed Web of Science ®Google Scholar
• Ellims P. H. Thymidine kinase isozymes in chronic lymphocytic leukemia. Br. J. Haematol. 1981; 49: 479–481
   PubMed Web of Science ®Google Scholar